Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings)
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings)
深入研究Biomarin制药股票：分析师观点（8个评级）
In the preceding three months, 8 analysts have released ratings for Biomarin Pharmaceutical (NASDAQ:BMRN), presenting a wide array of perspectives from bullish to bearish.
在过去的三个月中，有8位分析师发布了Biomarin Pharmaceutical（纳斯达克股票代码：BMRN）的评级，提出了从看涨到看跌的各种观点。
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
下表简要概述了分析师最近的评级，提供了对过去30天情绪变化的见解，并与前几个月进行了比较以获得整体视角。
Analysts have set 12-month price targets for Biomarin Pharmaceutical, revealing an average target of $100.88, a high estimate of $110.00, and a low estimate of $85.00. This current average has decreased by 5.05% from the previous average price target of $106.25.
分析师为Biomarin Pharmaceutical设定了12个月的目标股价，显示平均目标股价为100.88美元，最高估计为110.00美元，低估值为85.00美元。目前的平均价格较之前的平均目标价106.25美元下降了5.05％。
Exploring Analyst Ratings: An In-Depth Overview...
探索分析师评级...
登录免费看全文
登录/注册